Targeted Rifaximin Bead Compositions for GI-Specific Release
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Rifaximin's therapeutic potential is not fully realized due to varying absorption throughout the gastrointestinal tract, leading to inconsistent drug dissolution and systemic exposure, which can affect its efficacy in treating gastrointestinal disorders.
Innovation Solution
Formulating rifaximin compositions for targeted release to specific regions of the GI tract using nonpareil bead substrates and polymers, including pH-independent and pH-dependent polymers, to enhance luminal solubility and reduce systemic exposure.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If rifaximin is administered orally in conventional forms, then it provides favorable safety profile with minimal systemic exposure, but it results in inconsistent luminal concentrations and limited therapeutic potential due to variable absorption across GI regions
Solution Approach 1:
The patent segments the GI tract into distinct regions (upper, mid, lower) and develops separate bead formulations optimized for each region. Each bead type contains rifaximin with specific polymers and excipients tailored to the absorption characteristics and pH conditions of its target region, ensuring consistent and predictable drug release throughout the entire GI tract while maintaining minimal systemic exposure.
Solution Approach 2:
The invention applies local quality by creating region-specific formulations with different polymer compositions, ratios, and release characteristics for different GI segments. For example, upper GI beads use specific polymers optimized for acidic environments, while lower GI beads use polymers designed for neutral pH conditions, ensuring optimal drug release and absorption in each specific location.
2Quantity of substance
If rifaximin concentration is increased to enhance therapeutic effects, then luminal antimicrobial activity is improved, but systemic exposure increases causing unwanted side effects
Solution Approach 1:
By dividing the total rifaximin dose into multiple region-specific bead formulations, the patent achieves high luminal concentrations in each GI segment without requiring a proportionally high total dose. The segmented approach ensures that drug is released and absorbed optimally at each location, maximizing local therapeutic effect while minimizing the amount of drug that could potentially enter systemic circulation.
Solution Approach 2:
The patent employs preliminary action by pre-formulating rifaximin with region-specific polymers and excipients that control release characteristics before administration. This preliminary optimization of drug delivery ensures that rifaximin is released at the right location and rate, achieving maximum luminal concentration where needed while preventing excessive systemic absorption from the outset.
3Ease of manufacture
If conventional rifaximin tablets are used, then manufacturing is simple and cost-effective, but dissolution is inconsistent leading to variable drug exposure
Solution Approach 1:
The patent segments the formulation into multiple bead types, each optimized for specific GI regions. While this increases formulation complexity, each individual bead type can be manufactured using standardized processes, and the modular nature allows for scalable production. The segmentation enables precise control over dissolution characteristics of each bead type, ensuring consistent drug release in its target region.
Solution Approach 2:
The invention applies parameter changes by systematically varying polymer composition, ratio, and molecular weight across different bead formulations to optimize dissolution rates for specific GI regions. These controlled parameter changes ensure predictable and consistent drug release profiles while maintaining manufacturing feasibility through standardized formulation platforms.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The targeted release compositions increase solubilized rifaximin concentration in targeted areas, reducing systemic exposure and enhancing therapeutic effects in gastrointestinal disorders while minimizing side effects.
Implementation Method 1
the use of a soluble sugar sphere in the beads described herein was chosen, in part, because it provides an osmotic pressure that assists in driving dissolution of the rifaximin coated on the beads
Implementation Method 2
providing controlled rifaximin release, as demonstrated herein can reduce or eliminate inconsistencies in drug dissolution and unwanted side effects
Data Source
AI summary
Provided herein are GI specific rifaximin release compositions which can be formulated for targeted delivery of rifaximin to one or more portions of the GI tract. Methods of treating diseases and disorders with the disclosed compositions are also provided.